» Articles » PMID: 38607074

Unlocking the Future: Pluripotent Stem Cell-Based Lung Repair

Overview
Journal Cells
Publisher MDPI
Date 2024 Apr 12
PMID 38607074
Authors
Affiliations
Soon will be listed here.
Abstract

The human respiratory system is susceptible to a variety of diseases, ranging from chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis to acute respiratory distress syndrome (ARDS). Today, lung diseases represent one of the major challenges to the health care sector and represent one of the leading causes of death worldwide. Current treatment options often focus on managing symptoms rather than addressing the underlying cause of the disease. The limitations of conventional therapies highlight the urgent clinical need for innovative solutions capable of repairing damaged lung tissue at a fundamental level. Pluripotent stem cell technologies have now reached clinical maturity and hold immense potential to revolutionize the landscape of lung repair and regenerative medicine. Meanwhile, human embryonic (HESCs) and human-induced pluripotent stem cells (hiPSCs) can be coaxed to differentiate into lung-specific cell types such as bronchial and alveolar epithelial cells, or pulmonary endothelial cells. This holds the promise of regenerating damaged lung tissue and restoring normal respiratory function. While methods for targeted genetic engineering of hPSCs and lung cell differentiation have substantially advanced, the required GMP-grade clinical-scale production technologies as well as the development of suitable preclinical animal models and cell application strategies are less advanced. This review provides an overview of current perspectives on PSC-based therapies for lung repair, explores key advances, and envisions future directions in this dynamic field.

Citing Articles

Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option.

Lai S, Guo Z Stem Cell Res Ther. 2024; 15(1):312.

PMID: 39300523 PMC: 11414322. DOI: 10.1186/s13287-024-03940-9.

References
1.
Jacob A, Vedaie M, Roberts D, Thomas D, Villacorta-Martin C, Alysandratos K . Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat Protoc. 2019; 14(12):3303-3332. PMC: 7275645. DOI: 10.1038/s41596-019-0220-0. View

2.
Hawkins F, Kramer P, Jacob A, Driver I, Thomas D, McCauley K . Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells. J Clin Invest. 2017; 127(6):2277-2294. PMC: 5451263. DOI: 10.1172/JCI89950. View

3.
Stockley R, Turner A . α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med. 2014; 20(2):105-15. DOI: 10.1016/j.molmed.2013.11.006. View

4.
Wunderlich S, Haase A, Merkert S, Jahn K, Deest M, Frieling H . Targeted biallelic integration of an inducible Caspase 9 suicide gene in iPSCs for safer therapies. Mol Ther Methods Clin Dev. 2022; 26:84-94. PMC: 9234009. DOI: 10.1016/j.omtm.2022.05.011. View

5.
Sahabian A, Dahlmann J, Martin U, Olmer R . Production and cryopreservation of definitive endoderm from human pluripotent stem cells under defined and scalable culture conditions. Nat Protoc. 2021; 16(3):1581-1599. DOI: 10.1038/s41596-020-00470-5. View